An average woman spends around $2,000 per year to curb debilitating symptoms of menopausal hormone fluctuations.  

In 2025, 1 billion women will enter menopause. Even the most conservative estimate of that market is $600 billion. Seizing a measly 0.01% of it still adds up to $600 million annually.  

Female icons like Cameron Diaz, Gwyneth Paltrow and Naomi Watts know it and have realized this opportunity and launched or invested in startups looking to revolutionize the field. You can do the same with a startup that grew its revenue by 250% year over year.  

The Plagues Of The Big Pause  

All women will experience menopause and 99% are not provided care benefits at work,  according to a Gennev survey of 2,500 women. About 1 in 5 women either want to quit their job or have quit because of menopause, according to a national survey.  

The lack of support also has a detrimental effect on the economy. Between productivity loss and healthcare costs, the global economy suffers a $150 billion hit every year, according to  Bloomberg. Therein lies a major opportunity for disruption.  

A Way Out  

The current medical system is not equipped to treat the symptoms of menopause. AARP reports that of the 60% of women who seek menopause-related medical attention, 75% are left untreated — no wonder they’re turning to nature in their plea for hormonal balance.  

The Harvard Chan School of Public Health praised one natural ingredient for its potential health benefits, including weight control, cancer prevention and support for cardiovascular health.  Europeans had used it for 2,000 years before the wheel was invented but stopped by the 1800s. Other cultures have embraced it in many ways, which you realize if you've tried sushi.  

The natural solution in question is seaweed. It's the ultimate sustainable superfood with its power to absorb the healthiest elements from the seas and spread its benefits across the coastal regions. And its potential for hormonal treatment shouldn’t be tossed aside lightly. 

(Image courtesy of Rootless)  

Rootless is a company that compresses seaweed with 40+ essential macro and micronutrients to produce Daily Bites, a small nugget packed with nutrients and bioactives. The company conducted a consumer trial on women ages 27 to 70. The subjects consumed one Daily Bite per day for four weeks. The results were straightforward: 97% reported less dryness and hormonal acne, 86% felt less fatigue during the day and 83% noticed improved gut health, constipation and bloating.

(Image courtesy of Rootless)  

After achieving a product market fit, the company took to the market and experienced a meteoric rise.  

Between 2022 and 2023, the company grew its revenue by 251%. Even better, 50% of the revenue came from subscriptions and repeat purchases, which is a phenomenal sign of future  prospects for the product. Rootless, the creator of Daily Bites, has decided to open its doors to  accredited and nonaccredited investors. For a limited time, you can get in on the ground floor of  Rootless at only $0.80 per share. 

(Image courtesy of Rootless)  

Menopause and hormonal health are finally getting the recognition they deserve, but the $600  billion market is still there to be conquered. With one billion women soon to enter menopause,  investing in Rootless is a worthy avenue to explore.  

Click here to invest in Rootless.  

Want to get in on the action yourself?

Check out Benzinga's favorite options for investing in early-stage companies with potential for massive growth.

Read More On Startup Investing From Benzinga

Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information. This post contains sponsored advertising content. Read the 17-b disclosure.

The content that follows is for informational purposes only and not intended to be investing advice.

Disclaimer: Please be advised that alternative investments carry a risk of monetary loss. Neither Benzinga nor its staff recommends that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. All information contained on this website is provided as general commentary for informative and entertainment purposes and does not constitute investment advice. Benzinga will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on this information, whether specifically stated in the above Terms of Service or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.